Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters

JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli Ministry of Environmental Protection has granted the Company an amended radioactive license in the main manufacturing floor of its production facility in Jerusalem, increasing the maximum allowable amount of Thorium-228 for use and possession to produce Alpha DaRT sources from 30 milliCurie to 100 milliCurie. This expanded license could support the production of up to 300,000 Alpha DaRT sources per year in this facility.

In addition, the Company is also pleased to announce that it has received approvals from both the Israeli Ministry of Environmental Protection and the Animal Testing Council at the Israeli Ministry of Health for its pre-clinical radioactive laboratory at its Jerusalem headquarters, to conduct pre-clinical experiments utilizing mice and rats. The Company has now successfully completed all requirements for the certification of this laboratory and may begin submitting experimental protocols for ethics committee approval.

Alpha Tau CEO Uzi Sofer commented, “As our clinical trials continue to expand at an ever-increasing pace, led by our flagship ReSTART multicenter cutaneous SCC pivotal study in the U.S. alongside multiple trials in internal organs, the tremendous need for ongoing expansion of our manufacturing capacity, both in the U.S. and in Israel, remains critical to ensuring a steady supply of our Alpha DaRT treatments. Likewise, we are continuously growing our manufacturing and quality assurance teams to enable us to meet our current and future goals for the foreseeable future. In addition, with the exploration of combinations between the Alpha DaRT and other cancer therapies remaining a cornerstore of our strategy, our ability to test such combinations in-house in our own pre-clinical lab will allow us to optimize such combinations efficiently and help us examine a variety of possible combination trials for exploration in people desperately suffering from metastatic cancers.”